insights_auto
Why is KYNB down 2,92%?
Dive Deeperchevron_right
KYNB:NASDAQ
Kyntra Bio Inc
6,31 US$
arrow_downward
-2,92%(-0,19) 1D
6,30 US$
arrow_downward
-0,16% (-0,0100)bedtimeAfter hours
Closed: 2 ოქტ, 16:00:01 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for KYNB...
Open
6,60 US$
High
6,64 US$
Low
6,30 US$
Mkt. cap
25,55 მლნ.
Avg. vol.
25,22 ათ.
Volume
26,08 ათ.
P/E ratio
0,14
52-wk high
9,70 US$
52-wk low
6,30 US$
EPS
45,30 US$
Beta
1,05
Shares outstanding
4,05 მლნ.
No. of employees
34
Open
6,60 US$
High
6,64 US$
Low
6,30 US$
Mkt. cap
25,55 მლნ.
Avg. vol.
25,22 ათ.
Volume
26,08 ათ.
P/E ratio
0,14
52-wk high
9,70 US$
52-wk low
6,30 US$
EPS
45,30 US$
Beta
1,05
Shares outstanding
4,05 მლნ.
No. of employees
34
News stories
From web sources and news partners
Foreign Policy Journal
·
11 წუთის წინ
Supreme Court Cases Involving Apple (NASDAQ: AAPL), Exxon (NYSE: XOM), And Intel (NASDAQ: INTC) Could Reshape Investor Portfolios
Proactive financial news
·
1 საათის წინ
Nova Minerals to host investor webinar on Estelle and US antimony strategy
Simply Wall Street
·
30 წუთის წინ
Is New Client Win Altering The Investment Case For ACI Worldwide Stock?
USA Today
·
14 საათის წინ
Is a stock market correction coming? Most Americans think so
Profile
Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate.
On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB. Wikipedia
About Kyntra Bio Inc
CEO-
Employees34
Founded1 იან. 1993
Headquartersსან-ფრანცისკო, კალიფორნია, ამერიკის შეერთებული შტატები
Sector-
Websitekyntrabio.com